Top Markets
#1 Pleasing Gold Pleasing Gold +1,499.28%
#2 PulseChain PulseChain +58.12%
#3 Ontology Gas Ontology Gas +37.24%
#4 Merlin's Seal BTC Merlin's Seal BTC +33.75%
#5 ConstitutionDAO ConstitutionDAO +29.14%
#6 BOOK OF MEME BOOK OF MEME +29.14%
#7 Collect on Fanable Collect on Fanable +24.03%
#8 Neiro Neiro +22.56%
#9 Unit Pump Unit Pump +22.12%
#10 Pump.fun Pump.fun +22.12%
Coin of the day
Pleasing Gold Pleasing Gold
Pengaturan
Bahasa
BAHASA INDONESIA
Mata uang
USD
Tema
Aerpio Pharmaceuticals, Inc. Aerpio Pharmaceuticals, Inc.

Aerpio Pharmaceuticals, Inc.

ARPO
Peringkat dalam Saham #26440
Aerpio Pharmaceuticals Inc., a biopharmaceutical enterprise headquartered in... Aerpio Pharmaceuticals Inc., a biopharmaceutical enterprise headquartered in Blue Ash, Ohio, currently employs 27 full-time staff. The company's core mission revolves around the research and development of therapeutic solutions for ocular diseases. Its product pipeline is spearheaded by AKB-9778, with two additional programs, AKB-4924 and ARP-1536, also under development. AKB-9778 is a small molecule designed to activate the Tie-2 pathway, intended for the treatment of diabetic retinopathy (DR). AKB-4924, another candidate, functions as a selective stabilizer of hypoxia-inducible factor-1 alpha (HIF-1alpha) and is being investigated for its potential in treating inflammatory bowel disease (IBD). ARP-1536 is a humanized monoclonal antibody that targets the same pathway as AKB-9778. It operates by attaching to the extracellular domain of vascular endothelial protein tyrosine phosphatase (VE-PTP), thereby inhibiting its interaction with Tie-2. As of April 14, 2017, Aerpio had successfully concluded a Phase II clinical trial for AKB-9778, which involved 144 patients with diabetic macular edema. By the same date, a Phase Ia clinical trial for AKB-4924 in healthy volunteers had also been completed.
Harga Saham
$2.20
Terakhir disinkronkan: 2021-08-26
Kapitalisasi Pasar
$40.53M
Perubahan (1 hari)
-0.90%
Perubahan (1 tahun)
0.00%
Negara
US
Perdagangan Aerpio Pharmaceuticals, Inc. (ARPO)

Kategori

Healthcare
Rasio P/E untuk Aerpio Pharmaceuticals, Inc. (ARPO)
Rasio P/E per 2026 TTM: 0
Menurut laporan keuangan dan harga saham terbaru dari Aerpio Pharmaceuticals, Inc., rasio P/E saat ini (TTM) adalah 0. Pada akhir 2026, perusahaan memiliki rasio P/E sebesar 0.
Riwayat rasio P/E untuk Aerpio Pharmaceuticals, Inc. dari 2026 hingga 2026
Rasio P/E di akhir setiap tahun
Tahun Rasio P/E Mengubah
Tidak cukup data untuk tanggal yang disediakan.
Rasio P/E untuk perusahaan serupa atau pesaing
Perusahaan Rasio P/E Perbedaan Rasio P/E Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 32.46 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -7.93 -
US
Bagaimana cara membaca P/E ratio?

Rasio Harga/Laba (P/E) mengukur hubungan antara harga saham perusahaan dan laba per sahamnya.
P/E yang rendah namun positif menunjukkan perusahaan dengan laba tinggi dibandingkan valuasinya saat ini dan mungkin dianggap undervalued. P/E negatif tinggi (mendekati 0) menunjukkan perusahaan yang mengalami kerugian besar.

Perusahaan dengan P/E di atas 30 atau negatif umumnya dianggap sebagai "saham pertumbuhan", artinya investor mengharapkan pertumbuhan atau keuntungan di masa depan.

Perusahaan dengan P/E positif di bawah 10 dianggap sebagai "saham bernilai", artinya perusahaan sudah sangat menguntungkan dan pertumbuhannya kemungkinan tidak besar.